EMJ Oncology,
Journal Year:
2024,
Volume and Issue:
unknown, P. 39 - 48
Published: Oct. 29, 2024
The
metastatic
non-small
cell
lung
cancer
(mNSCLC)
treatment
landscape
has
vastly
expanded
over
the
past
two
decades
as
a
result
of
advancements
in
biomarker
testing.
However,
unmet
needs
remain
both
terms
options
for
some
patient
groups,
and
support
throughout
journey.
In
this
symposium,
Jarushka
Naidoo,
Consultant
Medical
Oncologist,
Beaumont
RCSI
Cancer
Centre,
Dublin,
Ireland;
Terri
Conneran,
KRAS
Kickers,
Charlotte,
North
Carolina,
USA;
Luis
Paz-Ares,
Chair
Oncology
Department,
Hospital
Universitario
12
de
Octubre,
Madrid,
Spain;
Alexander
Drilon,
Chief
Early
Drug
Development
Thoracic
Oncology,
Memorial
Sloan
Kettering
Center,
New
York,
USA,
focused
on
patient-centric
approaches
to
mNSCLC
treatment,
starting
with
advocacy
group
perspective
what
patients
want
from
their
care
team
during
panel
also
discussed
immuno-oncology
(I-O)
monotherapy
combination
therapy,
including
dual
I-O
therapies
programmed
death-ligand
1
(PD-L1)
tumour
expression
<1%,
well
KRASG12C-mutated
mNSCLC,
ongoing
trials
KRAS-targeted
agents.
addition,
latest
data
tyrosine
kinase
inhibitors
(TKI)
alterations
ROS1
NTRK
genes
were
discussed,
focusing
next-generation
TKIs.
Finally,
cases,
taking
into
account
specific
considerations
how
best
approach
decisions.
Cellular and Molecular Immunology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 10, 2024
While
immunotherapy
with
immune
checkpoint
inhibitors
(ICIs)
has
revolutionized
the
clinical
management
of
various
malignancies,
a
large
fraction
patients
are
refractory
to
ICIs
employed
as
standalone
therapeutics,
necessitating
development
combinatorial
treatment
strategies.
Immunogenic
cell
death
(ICD)
inducers
have
attracted
considerable
interest
partners
for
ICIs,
at
least
in
part
owing
their
ability
initiate
tumor-targeting
adaptive
response.
However,
compared
either
approach
alone,
regimens
involving
ICD
and
not
always
shown
superior
activity.
Here,
we
discuss
accumulating
evidence
on
therapeutic
interactions
between
oncological
settings,
identify
key
factors
that
may
explain
discrepancies
preclinical
findings,
propose
strategies
address
existing
challenges
increase
efficacy
these
combinations
cancer.
Cancers,
Journal Year:
2025,
Volume and Issue:
17(5), P. 906 - 906
Published: March 6, 2025
Non-small-cell
lung
cancer
(NSCLC)
remains
a
leading
cause
of
cancer-related
mortality
worldwide.
Immunotherapy
targeting
the
PD-1/PD-L1
axis
has
revolutionized
treatment,
providing
durable
responses
in
subset
patients.
However,
with
fewer
than
50%
patients
achieving
significant
benefits,
there
is
critical
need
to
expand
therapeutic
strategies.
This
review
explores
emerging
targets
immune
checkpoint
inhibition
beyond
PD-1/PD-L1,
including
CTLA-4,
TIGIT,
LAG-3,
TIM-3,
NKG2A,
and
CD39/CD73.
We
highlight
biological
basis
CD8
T
cell
exhaustion
shaping
antitumor
response.
Novel
approaches
additional
inhibitory
receptors
(IR)
are
discussed,
focus
on
their
distinct
mechanisms
action
combinatory
potential
existing
therapies.
Despite
advancements,
challenges
remain
overcoming
resistance
optimizing
patient
selection.
underscores
importance
dual
blockade
innovative
bispecific
antibody
engineering
maximize
outcomes
for
NSCLC
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
16
Published: Feb. 12, 2025
Background
This
study
aimed
to
investigate
the
prognostic
value
of
pretreatment
lactate
dehydrogenase
albumin
ratio
(LAR)
in
advanced
non-small
cell
lung
cancer
(NSCLC)
patients
treated
with
first-line
programmed
death
protein
1
(PD-1)
checkpoint
inhibitors
and
chemotherapy.
Methods
A
retrospective
cohort
was
conducted
on
NSCLC
PD-1
plus
chemotherapy
at
Guangxi
Medical
University
Cancer
Hospital.
The
receiver
operating
characteristic
(ROC)
analysis
determined
optimal
LAR
cutoff
values
for
prediction.
Univariate
multivariate
analyses
identified
independent
factors,
survival
curves
were
estimated
using
Kaplan-Meier
method.
Subgroup
evaluated
association
between
high
disease
progression
risk.
Results
total
210
enrolled,
a
mean
age
58.56
±
10.61
years
male
proportion
approximately
79.05%.
ROC
found
5.0,
resulting
sensitivity
78.87%
specificity
44.6%
(area
under
curve
0.622;
P
=
0.001).
Multivariate
revealed
significant
positive
overall
(OS)
after
adjusting
confounders
(HR
2.22,
95%
CI
1.25-3.96,
0.007).
confirmed
relationship
risk
across
all
patient
subgroups.
Conclusions
Pretreatment
may
be
potential
marker
receiving
large-scale,
prospective
is
necessary
confirm
these
findings.
Lung,
Journal Year:
2025,
Volume and Issue:
203(1)
Published: March 25, 2025
Lung
cancer
remains
the
leading
cause
of
cancer-related
mortality
worldwide.
Since
2024,
non-small-cell
lung
(NSCLC)
landscape
has
undergone
a
transformative
shift,
driven
by
11
FDA
approvals.
Recent
advances
in
molecular
profiling,
targeted
therapies,
and
immunotherapies
have
revolutionized
NSCLC
management,
ushering
an
era
personalized
treatment
with
improved
patient
outcomes.
The
increased
adoption
low-dose
computed
tomography
(LDCT)
for
screening
enhanced
early
detection,
enabling
intervention
at
more
curable
stages.
Molecular
diagnostics
now
play
pivotal
role
guiding
strategies,
actionable
genomic
alterations
(AGAs)
informing
use
EGFR,
ALK,
ROS1,
KRAS,
NRG1,
other
inhibitors
both
advanced
settings.
For
instance,
therapies
are
increasingly
being
integrated
into
early-stage
adjuvant
osimertinib
EGFR-mutated
alectinib
ALK-positive
demonstrating
substantial
survival
benefits.
Immunotherapy,
particularly
immune
checkpoint
inhibitors,
become
cornerstone
AGA-negative
NSCLC,
either
as
monotherapy
or
combination
chemotherapy,
is
utilized
perioperative
setting.
Furthermore,
emerging
such
bispecific
antibodies,
antibody-drug
conjugates
(ADCs),
novel
immunotherapeutic
agents
show
promise
addressing
resistance
mechanisms
improving
outcomes
advanced-stage
disease.
Although
new
challenges
arise,
evolving
paradigm
continues
to
prioritize
precision
medicine,
offering
hope
prolonged
quality
life
patients.
Cancers,
Journal Year:
2025,
Volume and Issue:
17(7), P. 1198 - 1198
Published: March 31, 2025
(1)
Background:
Exploring
real-world
data
(RWD)
regarding
immune-related
adverse
events
(irAEs)
is
crucial
to
better
understand
the
efficacy
and
safety
of
immunotherapy
in
cancer
patient
populations
excluded
from
clinical
trials.
An
analysis
was
conducted
evaluate
presumptive
predictive
causality
between
endocrine
irAEs
immune
check-point
inhibitors
(ICIs)
metastatic
non-small-cell
lung
(mNSCLC)
patients
treated
daily
practice
Romania.
(2)
Methods:
This
a
retrospective
cohort
study
mNSCLC
with
ICIs
tertiary
level
hospital
Romania
for
period
almost
seven
years,
November
2017
till
July
2024.
Endocrine
were
well
defined
as
any
occurring
autoimmune
endocrinopathy
during
related
immunotherapy.
The
endocrinologist
(M.C.C.O)
diagnosed,
treated,
followed
these
multidisciplinary
approach.
We
investigated
multiple
medical
variables
assess
their
impact
on
ICI
effectiveness.
Descriptive
statistical
analyses
performed.
(3)
Results:
Of
487
ICIs,
we
identified
215
who
evaluated
co-medications
therapy.
Forty-seven
(21.8%)
experienced
irAEs,
thyroiditis
being
most
frequent
prevalent
60%
cases.
statistically
significant,
correlated
(p
=
0.002)
survival
analysis.
Steroids
proton-pump
used
co-medication
had
negative
response
(4)
Conclusions:
might
be
considered
biomarkers
successful
patients.
Co-medication
major
influence
effectiveness
cutting-edge
therapies.
RWD
plays
an
important
role
oncology
whenever
trial
evidence
not
available
guide
decision.
